**Introduction**

Inflammatory bowel disease (IBD) is a chronic inflammatory condition produced by a combination of genetic factors and changes in endogenous enteric bacteria. IBD is characterized by an abnormal immune response and chronic inflammation of the intestine. An increased production of cytokines, including TNF-α, IL-1β, IL-23, IL-6, IL-8, and IL-17 are associated with IBD. Thus, compounds with the capability to inhibit these cytokines can be utilized as potential drugs for IBD [1]. The current treatment approaches for IBD include antibiotics, corticosteroids, immunosuppressants, TNF-α monoclonal antibodies, and compounds containing mesalamine [1].

In an effort to discover novel bioactive natural plant products for the potential future treatment of IBD, we examined the silymarin complex for cytokine inhibition. The silymarin complex is an extract of milk thistle seeds comprised of four major classes of flavonolignans, including silibinin, silychristin, silydianin, and isosilibinin. The major and most active constituent of silymarin is historically considered to be silibinin [2, 3]. These compounds are known for their antioxidant and anti-inflammatory properties [2].

---

**Key words**
silymarin, silibinin, isosilibinin, anti-inflammatory, cytokines, inflammatory bowel disease

**received** 02.07.2018  
**revised** 30.07.2018  
**accepted** 23.08.2018

**Bibliography**

DOI: [https://doi.org/10.1055/a-0733-3716](https://doi.org/10.1055/a-0733-3716)  
Planta Med Int Open 2018; 5: e55–e60  
© Georg Thieme Verlag KG Stuttgart · New York  
ISSN 2509-9264

**Correspondence**  
Leo R. Fitzpatrick  
Department of Pharmaceutical and Biomedical Sciences  
9700 West Taron Drive  
College of Pharmacy  
California Northstate University  
Elk Grove, CA 95757, USA  
Tel.: +1/916/686 8364, Fax: +1/916/631 8127  
lfitzpatrick@cnsu.edu
Milk thistle (or silymarin) has been predominantly investigated in human clinical trials involving subjects with hepatitis or cirrhosis [4–6]. In addition, smaller studies were reported that included patients with acute lymphoblastic leukemia, prostate cancer, breast cancer, and hepatocellular carcinoma [7]. Of relevance to this paper, silymarin showed positive results in a small clinical trial utilizing patients with ulcerative colitis, a form of IBD [8].

Recently, we reported that silymarin derivatives inhibited pro-inflammatory cytokine secretion from macrophage and colonic epithelial cell lines [9]. As a follow-up to that basic cell culture study, the ex vivo effects of fractions/compounds derived from silymarin were examined for inhibiting cytokine secretion from colonic strips of mice with/without dextran sulfate sodium (DSS)-induced colitis. Further, the in vitro effects of these silymarin derivatives were studied in relevant cell lines stimulated by colonic supernatants from mice with colitis.

Results
Colon lengths are typically measured in conjunction with the murine DSS colitis model as an indicator of colonic damage [10]. As shown in Table 1, treatment with DSS indeed significantly decreased the colon length as compared to the water treatment group. Disease activity indices (DAIs) in DSS-treated mice are used as a “clinical” indicator of bloody stools, diarrhea, and body weight loss [10]. The mean DAI (on study day 6) was found to be significantly increased in DSS-treated mice as compared to that in water-treated animals (Table 1). These results indicate that colitis was clearly established in our DSS-treated cohort of mice.

As suggested in Fig. 1a, using colonic strips from DSS-treated mice, the mean percent inhibition of basal MIP-2 secretion (relative to vehicle treatment) was: Fraction 2 (96 %) > isosilibinin (96 %) > silibinin (92 %) > crude fraction (75 %) > fraction 5 (69 %). Significant reductions (p < 0.05 vs. vehicle/DSS) were obtained with all silymarin derivatives (at a concentration of 200 μg/mL), although fraction 2 and isosilibinin were most effective. Silymarin fractions (as well as isosilibinin and silibinin) also reduced TNF-α secretion (Fig. 1b). However, statistical significance compared to vehicle treatment was only attained by ex vivo treatment with fraction 2 and isosilibinin.

Using colonic strips from mice with colitis, silymarin derivatives also attenuated dual (IL-1β + IL-23) cytokine-induced colonic IL-17 secretion at concentrations in the range of 20–200 μg/mL (Fig. 2). These derivatives demonstrated a dose-dependent inhibition pattern, with the exception of crude silymarin treatment. Significant inhibitions (at a concentration of 200 μg/mL) were found with all silymarin-related treatment groups.

Fig. 3 shows that ex vivo treatment with crude silymarin extract, two silymarin fractions, silibinin, and isosilibinin tended to also reduce dual cytokine-induced colonic IL-17 secretion from colonic strips of water-treated mice at concentrations in the range of 20–200 μg/mL. However, significant reductions (p < 0.05 vs. vehicle/stimulated) were only obtained by ex vivo treatment with the crude extract (200 μg/mL) and isosilibinin (100 and 200 μg/mL).

As illustrated in Fig. 4a, crude silymarin extract, isosilibinin, and caffeic acid phenethyl ester (CAPE; positive control drug) significantly (p < 0.05 vs. vehicle + colitis supernatant) attenuated colitis supernatant (CS)-stimulated TNF-α secretion by RAW 264.7 cells. Cell viability (as determined by the MTT assay) showed no significant reductions in viability compared to the untreated control group (Table 2). Therefore, the reductions in cytokine production by crude extract and/or isosilibinin cannot be accounted for by cellular toxicity.

Since isosilibinin was most effective for attenuating CS-induced cytokine secretion in the macrophage cell line, we also tested it for activity in a colonic epithelial cell line. Fig. 4b demonstrates that isosilibinin significantly attenuated CS-stimulated IL-8 secretion from HT29 cells (p < 0.05 vs. vehicle + CS). With this cell line, once

<table>
<thead>
<tr>
<th>Treatment group (number)</th>
<th>DAI (0–4 Scale)</th>
<th>Colon length (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water (n = 8)</td>
<td>0.1 ± 0.1</td>
<td>7.6 ± 0.2</td>
</tr>
<tr>
<td>DSS (n = 16)</td>
<td>1.8 ± 0.1</td>
<td>6.4 ± 0.2</td>
</tr>
</tbody>
</table>

* P < 0.05 vs. water (non-colitis mouse) control treatment group by unpaired t-test analyses.
again, no significant reductions in viability were found compared to the untreated control group (► Table 2).

Discussion

Historically, the most active constituent of silymarin is considered to be silibinin [2, 3]. Our previous study found that silibinin and isosilibinin containing fractions (numbers 2 and 5) of silymarin most potently inhibited proinflammatory cytokine secretion from macrophage and colonic epithelial cell lines [9]. Of note, fraction 2 contains predominantly isosilibinin, while fraction 5 contains predominantly silibinin [9]. These cell culture system-derived results were the impetus for this study, which was to further characterize optimal in vitro and ex vivo anti-inflammatory/anti-colitis activities of silymarin-derived flavonolignans.

DSS induced colitis in mice is an established IBD model, which is commonly used for novel compound testing. IL-17, TNF-α, and MIP-2 are upregulated in conjunction with this murine DSS colitis model [10, 11]. In this regard, MIP-2 (a mouse equivalent to human IL-8) is chemotactic for neutrophils and induces localized colonic neutrophil infiltration associated with colitis [11]. Secretion of MIP-2 and TNF-α from colonic strips of mice was significantly attenuated by ex vivo treatment with silymarin derivatives, particularly fraction 2 (containing predominantly isosilibinin) and isosilibinin itself (► Fig. 1).

Kleinscheck et al. [12] reported increased levels of IL-17 secretion from lamina propria leukocytes of patients with IBD upon stimulation with IL-23 and IL-1β. Moreover, Coccia and colleagues [13] described the production of IL-17 from IL-1β-stimulated innate lymphoid cells, and the synergistic effects of IL-23 and IL-1β on chronic intestinal inflammation. Furthermore, our laboratory previously described enhanced IL-17 secretion, by dual IL-23 and IL-1β stimulation, from colonic strips of mice with DSS-induced colitis [10]. This enhanced IL-17 secretion is dependent on the stimulation of NF-kB and STAT3 signal transduction pathways [1, 10]. Recently, our laboratory showed that a documented anti-inflammatory/anti-colitis drug (GSK805) blocked IL-17 secretion from murine colonic strips [14, 15].

Using this colonic strip model system [10], our study shows that ex vivo treatment with various silymarin derivatives resulted in clear inhibition of dual cytokine-stimulated IL-17 secretion (► Fig. 2). Interestingly, treatment with fraction 2 and isosilibinin as well as silibinin was particularly effective for attenuating IL-17 secretion. In order to assess the effects of these flavonolignans on “physiological inflammation”, we also determined their activities against dual cytokine-stimulated IL-17 secretion from colonic strips of mice without colitis. Once again, isosilibinin was particularly effective for blocking cytokine secretion (► Fig. 3).

Previously, our laboratory showed that gliotoxin and CAPE, two known NF-κB inhibitors, blocked cytokine production from macrophage and colonic epithelial cell lines [16, 17]. Notably, gliotoxin inhibited CS-stimulated TNF-α secretion by macrophages [16]. Utilizing these previous experimental paradigms, we conducted similar types of experiments for this study. Initial dose-response experiments (data not shown) indicated that 50 μL of CS was optimal for stimulating TNF-α secretion by macrophages. This amount of CS was used for subsequent experiments. Our results showed that isosilibinin (200 μg/mL) significantly inhibited CS-induced proinflammatory cytokine/chemokine secretion from two different cell lines (► Fig. 4) with relevance to the pathogenesis of colitis [16, 17].
The theory behind stimulating these cell lines with CS is that unlike typical in vitro experimental conditions [9], the cytokines/chemokines involved in inflammatory responses of colitis are not singular but multifactorial. Therefore, there is upregulation of multiple cellular signaling pathways and proinflammatory cytokines [1, 16]. As a result, such CS studies, as well as ex vivo studies, are likely better representative models to test the efficacy of novel compounds prior to in vivo testing. In this regard, preliminary data from our laboratory showed that silymarin fractions could inhibit cytokine secretion from a dual culture system, which involves interactions between macrophage and colonic epithelial cells [18].

Our current data are most likely consistent with the inhibition of a transcription factor(s) by the silymarin-derived fractions/compounds [19]. CAPE (a known NF-κB inhibitor) was effective for inhibiting CS-stimulated TNF-α secretion from macrophages (▶ Fig. 4a) [17]. Moreover, previous investigators reported that silibinin treatment inhibited TNF-α-induced NF-κB activation in HT29 cells [20]. Therefore, this type of mechanism of action could be the basis for the observed block of cytokine secretion found with flavonolignans in this study [9, 20].

Previous studies have demonstrated the efficacy of silymarin (alone or in combination with ursodeoxycholic acid) in a rat TNBS (trinitrobenzene sulfonic acid) colitis model [21, 22]. Moreover, silymarin also showed positive results in a small clinical trial utilizing patients with ulcerative colitis [8]. Our results imply that a promising therapeutic approach for anti-colitis drugs could be with silymarin-derived compounds. Specifically, the overall data profile suggests that fraction 2 (containing predominantly isosilibinin), or isosilibinin itself, would be optimal for follow-up in vivo testing in animal models of IBD. Potentially, this research path could lead to further identification of specific silymarin-derived flavonolignans for potential therapeutic use in patients with IBD.

### Materials and Methods

#### Chemical reagents and reference drugs

Silymarin, isosilibinin, and CAPE were purchased from Sigma-Aldrich. The MTT assay kit was from ThermoFisher Scientific. All cytokine ELISA kits were obtained from R&D Systems.

#### Plant material

The seeds of milk thistle, used in the investigation to create the crude extract, were obtained from a commercial supplier (San Franc...
The powdered seeds (30 g) were extracted into a residue. The residue was then chromatographed on a flash chromatography system. Fractions (15 mL each) were monitored by TLC on silica gel, as described previously [23]. Silimarin fraction compositions were confirmed by LC/MS analyses and characterized employing methods described previously by our laboratory [9]. The individual pure compounds included silibinin A & B, silychristin, taxifolin, isosilibinin A & B, and apigenin. Fraction 2 contained isosilibinin A & B (major, 1:3 ratio), silibinin A & B (1:3 ratio), silychristin (minor), and taxifolin. Fraction 5 contained silybinin A & B (major 1:1 ratio), silychristin (minor), isosilibinin A & B (minor, 1:4 ratio), and apigenin [9].

Dextran sulfate sodium colitis model

We utilized the method described previously by our laboratory [10]. Colitis was induced in male C57BL/6 mice (n = 16) by giving 2% DSS drinking water for a 6-day period. Control mice (n = 8) were given untreated water. During the in-life portion of the study, DAI scores (0–4 severity scale) were recorded on a daily basis [10]. Further, colon lengths were measured on study day 6. The associated animal protocol was approved by IACUC’s at California Northstate University (Elk Grove, CA; Protocol # is CNU0001, with an approval date of 12/18/2015) and Antibodies Incorporated (Davis, CA; Protocol # is 0416-1, with an approval date of 4/28/2016).

Ex vivo colonic strip model

Employing a 24-h colonic culture system, the ex vivo effects of crude silymarin extract, two different silymarin fractions, as well as commercially derived silibinin and isosilibinin (20, 100, and 200 μg/mL), were examined [10]. Colonic strips obtained from mice with/without DSS-induced colitis were used, and the secretion of MIP-2, TNF-α, and IL-17 in cell culture media was determined using appropriate ELISA kits.

Murine macrophage (RAW 264.7) cell line

One hour prior to stimulation of murine-derived macrophages, crude silymarin extract, two different silymarin fractions, commercially derived silibinin and isosilibinin (200 μg/mL) as well as CAPE (positive control drug) were added to the cell culture. RAW 264.7 murine macrophages were then stimulated with the colitis supernatant (50 μL). The colitis supernatant was obtained from the vehicle/DSS group using the colonic strip model. After 4 h, the cell culture supernatant was collected for determination of TNF-α using an appropriate ELISA kit. Cell viability was determined by the MTT assay.

Colonic epithelial (HT-29) cell line

One hour prior to stimulation of human colonic epithelial cells, isosilibinin was added to the cell culture system at a concentration of 200 μg/mL. HT-29 colonocytes were then stimulated with the colitis supernatant (50 μL). Once again, the colitis supernatant was obtained from the vehicle/DSS group using the colonic strip model. After 4 h, the cell culture supernatant was collected for determination of IL-8 using an ELISA kit. Cell viability was assessed by the MTT assay.

Statistical analyses

All statistics were done with GraphPad Prism. Testing for normal distribution of the data was done by the D’Agostino & Pearson omnibus normality test. Student’s t-test for unpaired data was utilized for analyses of the murine colitis parameters. This statistical method was also used to analyze the in vitro cell culture data. If ANOVA testing showed a difference between treatment groups means, we then utilized Sidak’s multiple comparison tests for analyzing the ex vivo colonic strip data. Statistical significance was attained if the p value was < 0.05 for the analyses performed.

Acknowledgements

We acknowledge that Leo Fitzpatrick and Ella Mokrushin contributed equally to the first authorship of this manuscript. We would also like to acknowledge the research personnel at Antibodies Incorporated (Davis, CA) for their help with the animal husbandry associated with our study.

Conflict of Interest

The authors declare no conflict of interest.

References

[10] Fitzpatrick LR, Stonesifer E, Small JS, Liby KT. The synthetic triterpenoid (CDDO-Im) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis in mice. Inflammopharmacology 2014; 22: 341–349


